In addition, there are literatures suggesting that somatic gain-of-function mutations of PTPN11 are presented in breast cancer [30, 31], lung adenocarcinomas [32] and etc. BRAF is ranked as the second impactful driver gene which is an important event in the development of papillary thyroid cancer [33]. This evidence concerns the gene PTPN11 and breast cancer.